Figure 2.

Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) in patients with axial spondyloarthritis before and after 12 and 36 to 52 weeks of treatment with adalimumab. *P < 0.05. ns, not significant.

Appel et al. Arthritis Research & Therapy 2008 10:R125   doi:10.1186/ar2537
Download authors' original image